Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.

The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.

The invention relates generally to the field of molecular biology and microbiology. Provided herein is an expression construct encoding a fusion protein. In one embodiment, there is provided an expression construct encoding a fusion protein, the expression construct comprising a nucleic acid encoding a first polypeptide for expression and a second polypeptide derived from the cell wall targeting region of a Lactobacillus plantarum Lys2 autolysin, wherein the first and second polypeptides are joined to form a fusion protein. In a specific embodiment, the second polypeptide comprises the CAD4a domain, which is a truncated domain containing only R1-R3 of the five-repeat SH3_5 domain of the Lys2 autolysin. Provided herein is also a fusion protein and the use of a fusion protein as defined herein.

The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patients internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding an improved leucine catabolism enzyme with higher activity and/or specificity for leucine over other branched chain amino acids, such as isoleucine or valine. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of leucine, isoleucine, and/or valine using the pharmaceutical compositions disclosed herein.

Disclosed herein is a composition that includes Lactobacillus plantarum LP28 deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 3346, and Streptococcus thermophilus ST30 deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under an accession number DSM 32788. Also disclosed herein are an animal feed comprising the composition, and a method for improving pork quality, which comprises administering to a pig the composition.

Provided herein are fermented beverages comprising symbiotic microbial communities, and methods of production thereof.

The present invention relates to compositions and methods for producing fermented milk products with increased amount of probiotic bacteria. In particular, the invention relates to a process for producing a fermented milk which comprises adding to a milk base (i) a starter culture comprising at least one lactose-deficient Streptococcus thermophilus strain, which is capable of metabolizing a non-lactose carbohydrate, and at least one lactose-deficient Lactobacillus strain, which is capable of metabolizing a non-lactose carbohydrate, (ii) one or more non-lactose carbohydrate capable of being metabolized by the lactic acid bacteria, in an amount measured so as to become depleted when the pH of the fermented milk product is between 4.9 and 5.5 and (iii) a probiotic strain selected from a Lactobacillus strain and a Bifidobacterium strain. In addition, the present invention relates to compositions and to fermented milk food or feed products produced by the process of the invention.

The present invention provides for a one-pot enzymatic approach which does not require removal of the enzyme and purification of the intermediate after deglycosylation step, and the Endo-S treatment is able to do both deglycosylation and transglycosylation. The one-pot strategy of the present invention enables chemoenzymatic synthesis of an azido-tagged N-glycoform of monocloncal antibodies which could be further modified through orthogonal chemical ligation for various applications.

The present invention relates to a Lactococcus chungangensis strain having preventive and reductive effects on fatty liver or metabolic syndrome. More particularly, the present invention relates to a composition at least one selected from the group consisting of the strain, a culture containing the strain, and a fermented material of the strain as an active ingredient for preventing, alleviating, and treating fatty liver or metabolic syndrome.

The disclosure relates to live biotherapeutic products, probiotics, pharmaceutical compositions comprising said probiotics, and methods of using them to treat various human diseases. In some aspects, the disclosure provides such compositions comprising strains of the bacterium Streptococcus australis and their uses in treating metabolic-related diseases or disorder.